François-Xavier Gros

11PUBLICATIONS
46CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumoursGene and molecular therapyTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 09, 2026
Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.

Emilie Charton, Amélie Anota, Emmanuel Bachy

|Oct 22, 2025
Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry.

Federico Erbella, Emmanuel Bachy, Guillaume Cartron

|May 01, 2025
TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas.

Pierre Stephan, Roberta Di Blasi, Louise Roulin

|Apr 03, 2025
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study.

Guillaume Cartron, Roch Houot, Yassine Al Tabaa

|Jan 28, 2025
Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study.

Xavier Phina-Ziebin, Emmanuel Bachy, François-Xavier Gros

|May 14, 2024
Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.

Roch Houot, Emmanuel Bachy, Guillaume Cartron

Pageof 2

Frequent Collaborators

10 joint publications

Emmanuel Bachy

9 joint publications

Roch Houot

7 joint publications

Sylvain Choquet

5 joint publications

Roberta Di Blasi